Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.72 USD
+0.17 (6.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T-cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
Allogene is currently focused on developing its lead candidate, cema-cel, as a frontline treatment for patients with large B cell lymphoma (LBCL). In this regard, management ...
Company Summary
South San Francisco, CA-based Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company primarily focused on developing and commercializing genetically engineered allogeneic T-cell therapies for cancer treatment.
The company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — ALLO-501, cemacabtagene ansegedleucel (cema-cel, or formerly ALLO-501A), ALLO-605, ALLO-316 and ALLO-715 — and a monoclonal antibody (mAB), ALLO-647.
Allogene is currently focused on developing its lead candidate, cema-cel, as a frontline treatment for patients with large B cell lymphoma (LBCL). In this regard, management has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in LBCL patients.
ALLO-715 and ALLO-605 are being evaluated in the phase I UNIVERSAL study and phase I IGNITE study, respectively, for the same indication — r/r multiple myeloma (MM). ALLO-605 is also the company’s first anti-BCMA TurboCAR T cell therapy. ALLO-316 is being evaluated in a phase I TRAVERSE study for advanced or metastatic renal cell carcinoma (RCC). The mAB candidate, ALLO-647, is part of the lymphodepletion regimen, which is likely to increase the potency of allogeneic CAR T cell therapies.
The company has licensing agreements with companies, including Pfizer, for gaining rights to several of the latter's technologies or candidates.
With no marketed products in its portfolio, Allogene only generates collaboration revenues. The company generated $0.1 million in 2023, down 39% year over year.
General Information
Allogene Therapeutics, Inc
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-457-2700
Fax: NA
Email: ir@allogene.com
| Industry | Medical - Biomedical and Genetics |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 9/30/2024 |
| Earnings Date | 11/7/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | -0.34 |
| Current Year EPS Consensus Estimate | -1.41 |
| Estimated Long-Term EPS Growth Rate | NA |
| Earnings Date | 11/7/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 2.56 |
| 52 Week High | 5.78 |
| 52 Week Low | 2.01 |
| Beta | 0.84 |
| 20 Day Moving Average | 1,807,969.75 |
| Target Price Consensus | 9.43 |
| 4 Week | 0.74 |
| 12 Week | 17.24 |
| YTD | -15.27 |
| 4 Week | 1.13 |
| 12 Week | 9.37 |
| YTD | -29.45 |
| Shares Outstanding (millions) | 209.11 |
| Market Capitalization (millions) | 568.78 |
| Short Ratio | NA |
| Last Split Date | NA |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | NA |
| Change in Payout Ratio | NA |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | NA |
| Trailing 12 Months | NA |
| PEG Ratio | NA |
| vs. Previous Year (Q0/Q-4) | 39.62% |
| vs. Previous Quarter (Q0/Q-1) | 15.79% |
| vs. Previous Year (Q0/Q-4) | -57.69% |
| vs. Previous Quarter (Q0/Q-1) | 4.76% |
| Price/Book | 1.10 |
| Price/Cash Flow | NA |
| Price / Sales | 4,375.27 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | -50.24 |
| 3/31/24 | -50.81 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | -40.21 |
| 3/31/24 | -40.82 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 12.25 |
| 3/31/24 | 12.80 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 12.25 |
| 3/31/24 | 12.80 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | NA |
| 3/31/24 | -212,951.53 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | NA |
| 3/31/24 | -223,139.98 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | -324,910.44 |
| 3/31/24 | -224,843.83 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 2.46 |
| 3/31/24 | 2.70 |
| 9/30/24 | NA |
| 6/30/24 | NA |
| 3/31/24 | NA |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 0.00 |
| 3/31/24 | 0.00 |
| 9/30/24 | Pending Next EPS Report |
| 6/30/24 | 0.00 |
| 3/31/24 | 0.00 |